Selkoe spoke to a number of topics in the Alzheimer space, including the challenges in the field and his excitement for the future.
Dennis Selkoe, MD
Advertisement
Articles by Dennis Selkoe, MD
The results conclude that treatment with crenezumab was associated with a consistent decrease in Aβ oligomer levels in the CSF.
Advertisement
Latest Updated Articles
Dennis Selkoe, MD: Current Challenges in Alzheimer Disease and Hope for the FuturePublished: August 19th 2018 | Updated:
- Dennis Selkoe, MD: Crenezumab Significantly Reduces Aβ Oligomers in CSF
Published: August 8th 2018 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials
2
GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease
3
FDA Approves New Intrathecal Administration Route for Spinal Muscular Atrophy Gene Therapy
4
Insight the Future of Anti-Tau Drug Development for Alzheimer Disease
5
